Clinical Trial: A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07843056) titled 'A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.' on Sept. 21.

Brief Summary: A phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole).

A total of 121 participants were randomized and assigned to either 1 of 2 treatment groups in a 1:1 ratio.

Study Start Date: May 10, 2022

Study Type: INTERVENTIONAL...